| Year | Q2 2024 | Q1 2024 |
|---|---|---|
| Total Revenue | 1.46B | 1.55B |
| Cost of Revenue | 326.96M | 775.16M |
| Gross Profit | 1.13B | 770.08M |
| Operating Expenses | 1.13B | 344.54M |
| Research and Development | 0 | 0 |
| Selling, General & Administrative Expenses | 0 | 344.54M |
| Selling & Marketing Expenses | 0 | 0 |
| General & Administrative Expenses | 0 | 0 |
| Other Expenses | 1.13B | 0 |
| Operating Income | 335.2M | 425.54M |
| Total Other Income/Expenses Net | 86.89M | 61.19M |
| Income Before Tax | 422.09M | 486.73M |
| Income Tax | 88.16M | 136.97M |
| Net Income | 328.33M | 341.52M |
| Basic EPS | 2.94 | 3.05 |
| EPS Diluted | 2.93 | 3.05 |
| Basic Average Shares | 111.68M | 111.97M |
| Diluted Average Shares | 112.06M | 111.97M |
| EBITDA | 520.33M | 581.6M |
Advanced Enzyme Technologies Limited
ADVENZYMES.NS
NSE
276.45INR5.3 (0.33%)
ADVENZYMES.NS Financial Statements
Retained Earning Schedule
| Year |
|---|
| Retained Earnings (Previous Year) |
| Net Income |
| Stock Repurchases |
| Dividend Paid |
| Retained Earnings |
| Other Distributions |
PPE Schedule
| Year |
|---|
| Gross PPE |
| Annual Depreciation |
| Capital Expenditure |
| Net PPE |
Intangible and Goodwill Schedule
| Year |
|---|
| Acquisitions and Adjustments |
| Goodwill (Previous Year) |
| Goodwill |